Table 1.
Patient characteristics.
| Characteristic | All Patients (n = 171) | HEDtotal Low (n = 46) | HEDtotal High (n = 125) | p-Value |
|---|---|---|---|---|
| Follow-up after HSCT (mo.) | ||||
| Median | 59.4 | 51.6 | 62.6 | |
| Range | 2.1–173.3 | 2.1–173.3 | 5.5–127.8 | |
| Age at Allo-HSCT (yr.) | ||||
| Median | 56 | 59 | 55 | 0.30 † |
| Range | 21–75 | 21–71 | 22–75 | |
| Sex (no. (%)) | ||||
| Male | 98 (57.3) | 28 (60.9) | 70 (56.0) | 0.57 ‡ |
| Female | 73 (42.7) | 18 (39.1) | 55 (44.0) | |
| Karnofsky index (no. (%)) | 0.23 § | |||
| ≥90 | 115 (67.3) | 31 (67.4) | 84 (67.2) | |
| <90 | 35 (20.5) | 12 (26.1) | 23 (18.4) | |
| n.a. | 21 (12.3) | 3 (6.5) | 18 (14.4) | |
| WHO 2016 subtype (no. (%)) | ||||
| RGN | 86 (50.3) | 21 (45.7) | 65 (52.0) | 0.22 § |
| MDS-related | 31 (18.1) | 13 (28.3) | 18 (14.4) | |
| Therapy-related | 8 (4.7) | 2 (4.3) | 6 (4.8) | |
| NOS | 46 (26.9) | 10 (21.7) | 36 (28.8) | |
| EBMT risk score (no. (%)) | ||||
| 1 | 3 (1.8) | 1 (2.2) | 2 (1.6) | 0.23 § |
| 2 | 28 (16.4) | 6 (13.0) | 22 (17.6) | |
| 3 | 52 (30.4) | 8 (17.4) | 44 (35.2) | |
| 4 | 32 (18.7) | 11 (23.9) | 21 (16.8) | |
| 5 | 38 (22.2) | 14 (30.4) | 24 (19.2) | |
| 6–7 | 10 (5.8) | 3 (6.5) | 7 (5.6) | |
| n.a. | 8 (4.7) | 3 (6.5) | 5 (4.0) | |
| ELN risk group ¶ (no. (%)) | ||||
| Favorable | 19 (11.1) | 5 (10.9) | 14 (11.2) | 0.81 § |
| Intermediate | 110 (64.3) | 32 (69.6) | 78 (62.4) | |
| Adverse | 26 (15.2) | 9 (19.6) | 17 (13.6) | |
| n.a. | 16 (9.4) | 0 (0.0) | 16 (12.8) | |
| HSCT setting (no. (%)) | ||||
| 1st line consolidation | 106 (62.0) | 25 (54.3) | 81 (64.8) | 0.44 § |
| Salvage therapy || | 42 (24.6) | 14 (30.4) | 28 (22.4) | |
| Relapse | 23 (13.5) | 7 (15.2) | 16 (12.8) | |
| Conditioning regimen (no. (%)) | ||||
| FLAMSA | 10 (5.8) | 4 (8.7) | 6 (4.8) | 0.32 § |
| FLAMSA-Flu/Bu | 41 (24.0) | 16 (34.8) | 25 (20.0) | |
| Flu/TBI | 16 (9.4) | 4 (8.7) | 12 (9.6) | |
| Cy/TBI | 19 (11.1) | 3 (6.5) | 16 (12.8) | |
| Bu/Cy | 24 (14.0) | 5 (10.9) | 19 (15.2) | |
| Flu/BCNU/Mel | 8 (4.7) | 1 (2.2) | 7 (5.6) | |
| Flu/Bu | 27 (15.8) | 8 (17.4) | 19 (15.2) | |
| Flu/Treosulfan | 18 (10.5) | 2 (4.3) | 16 (12.8) | |
| Other | 8 (4.7) | 3 (6.5) | 5 (4.0) | |
| Remission at HSCT (no. (%)) | 0.16 § | |||
| CR/CRi | 103 (60.2) | 22 (47.8) | 81 (64.8) | |
| PR | 23 (13.5) | 8 (17.4) | 15 (12.0) | |
| RD | 37 (21.6) | 13 (28.3) | 24 (19.2) | |
| n.a. | 8 (4.7) | 3 (6.5) | 5 (4.0) | |
| Donor (no. (%)) | ||||
| HLA-ident sibling | 63 (36.8) | 23 (50.0) | 40 (32.0) | 0.03 § |
| HLA-ident foreign donor | 108 (63.2) | 23 (50.0) | 85 (68.0) |
Abbreviations: BCNU, Carmustine; Bu, Busulfan; CR/PR, complete/partial remission; Cy, Cyclophosphamide; ELN, European Leukemia Network; FLAMSA, fludarabine cytarabine, amsacrine ± irradiation (depending on additional therapy); Flu, fludarabine; HCST, hematopoietic stem cell transplantation; Mel, melphalan; mo., months; n.a., not available; NOS, not otherwise specified; RD, refractory disease; RGN, recurrent genetic alterations; yr., years; TBI, total body irradiation (combined ≥ 8 Gy); †, Mann–Whitney-Test; ‡, Fisher’s exact test; §, Pearson’s chi-squared test; ¶, according to the respective current ELN classification [14,15] (when applying the ELN 2010 classification [15], Intermediate-I and Intermediate-II were grouped together); and ||, < CR after induction therapy.